Bolt Biotherapeutics (BOLT) - Total Liabilities
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has total liabilities worth $32.95 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Bolt Biotherapeutics (BOLT) cash conversion ratio to assess how effectively this company generates cash.
Bolt Biotherapeutics - Total Liabilities Trend (2018–2024)
This chart illustrates how Bolt Biotherapeutics's total liabilities have evolved over time, based on quarterly financial data. Check BOLT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Bolt Biotherapeutics Competitors by Total Liabilities
The table below lists competitors of Bolt Biotherapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Workspace Group PLC
LSE:WKP
|
UK | GBX955.40 Million |
|
Tempo Inti Media Tbk
JK:TMPO
|
Indonesia | Rp206.41 Billion |
|
Finexia Financial Group Ltd
AU:FNX
|
Australia | AU$134.96 Million |
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
USA | $7.83 Million |
|
Medicure Inc
V:MPH
|
Canada | CA$9.41 Million |
|
Azevedo & Travassos S.A
SA:AZEV3
|
Brazil | R$887.14 Million |
|
Batero Gold Corp
V:BAT
|
Canada | CA$2.49 Million |
|
Bon Natural Life Ltd
NASDAQ:BON
|
USA | $27.19 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Bolt Biotherapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Bolt Biotherapeutics.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bolt Biotherapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bolt Biotherapeutics (2018–2024)
The table below shows the annual total liabilities of Bolt Biotherapeutics from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $42.43 Million | -9.80% |
| 2023-12-31 | $47.04 Million | -16.44% |
| 2022-12-31 | $56.30 Million | -2.25% |
| 2021-12-31 | $57.60 Million | -61.98% |
| 2020-12-31 | $151.49 Million | +60.66% |
| 2019-12-31 | $94.29 Million | +195.42% |
| 2018-12-31 | $31.92 Million | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more